Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 4
Submit an article Journal homepage
351
Views
5
CrossRef citations to date
0
Altmetric
Original Article

TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease

Tore GrimstadDepartment of Internal Medicine, Stavanger University Hospital, Stavanger, Norway; Correspondence[email protected]
View further author information
,
Inger Marie SkoieDepartment of Dermatology, Stavanger University Hospital, Stavanger, Norway; View further author information
,
Jessica DoernerDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA; View further author information
,
Kjetil IsaksenDepartment of Internal Medicine, Stavanger University Hospital, Stavanger, Norway; View further author information
,
Lars KarlsenDepartment of Internal Medicine, Stavanger University Hospital, Stavanger, Norway; View further author information
,
Lars AabakkenDepartment of Medical Gastroenterology, Oslo University Hospital – Rikshospitalet, Oslo, Norway; View further author information
,
Roald OmdalDepartment of Internal Medicine, Stavanger University Hospital, Stavanger, Norway; ;Department of Clinical Science, University of Bergen, Bergen, NorwayView further author information
&
Chaim PuttermanDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA; View further author information
 show all
Pages 420-424 | Received 04 Nov 2016, Accepted 12 Dec 2016, Published online: 31 Dec 2016

References

  • Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol. 2012;92:265–279.
  • Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat Inflamm. 2014;2014:325129.
  • Wen J, Doerner J, Weidenheim K, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015;60:40–50.
  • Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun. 2006;27:242–250.
  • Doerner JL, Wen J, Xia Y, et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol. 2015;135:1986–1995.
  • Xia Y, Herlitz LC, Gindea S, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2015;26:1053–1070.
  • Michaelson JS, Wisniacki N, Burkly LC, et al. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun. 2012;39:130–142.
  • Dohi T, Borodovsky A, Wu P, et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology. 2009;136:912–923.
  • Kawashima R, Kawamura YI, Oshio T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice—a pathway associated with ulcerative colitis. Gastroenterology. 2011;141:2119–2129.
  • Kaplan M, Yuksel M, Ates I, et al. Are sTWEAK and IL-17A levels in inflammatory bowel disease associated with disease activity and etiopathogenesis? Inflamm Bowel Dis. 2016;22:615–622.
  • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.
  • Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113–124.
  • Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–989.
  • Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6:551.
  • Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–1640.
  • Korolkova OY, Myers JN, Pellom ST, et al. Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn's colitides. Clin Med Insights Gastroenterol. 2015;8:29–44.
  • Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016;64:44–50.
  • Fragoso-Loyo H, Atisha-Fregoso Y, Nunez-Alvarez CA, et al. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus. Lupus. 2016;25:364–369.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.